Brooks Laboratories rights issue history
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Brooks Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹59.90up ₹0.18 (0.30%)BSE ₹60.00
Share price at the NSE close on 28 Oct 2026. Previous close ₹59.72.
28 Oct: open ₹59.55, high ₹61.42, low ₹58.93
52-week range of traded prices to 28 Oct 2026
₹36.30Low, 30 Mar 2026₹116.00High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹176 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.36
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.44
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 23,69748.3% delivered
Brooks Laboratories has made no bonus issue or split since Sep 2011; its other changes to its shares on record are below.
Rights issues
Every one on record, latest first.
- Rights issue · 28 Jul 2023 · record date 28 Jul 20231 new share offered for every 16 held at ₹75 a share, face value plus a premium of ₹65. Open 7 Aug 2023 to 22 Aug 2023.
- Rights issue · 11 Feb 2020 · record date 12 Feb 20209 new shares offered for every 20 held at ₹20 a share, face value plus a premium of ₹10. Open 19 Feb 2020 to 12 Mar 2020.